Salarius Pharmaceuticals (FRA:FP1) ROCE % : -158.89% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Salarius Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -158.89%.

Salarius Pharmaceuticals ROCE % Historical Data

The historical data trend for Salarius Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals ROCE % Chart

Salarius Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-84.12

-45.11

-43.21

-98.42

-161.40

Salarius Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-270.10	-226.27	-140.92	-67.49	-158.89

Salarius Pharmaceuticals ROCE % Calculation

Salarius Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.825	/	( ( (13.831 - 4.027)	+	(6.04 - 1.191) )	/ 2 )
	=	-11.825	/	( (9.804	+	4.849)	/ 2 )
	=	-11.825	/	7.3265
	=	-161.40 %

Salarius Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-6.52	/	( ( (6.04 - 1.191)	+	(4.493 - 1.135) )	/ 2 )
	=	-6.52	/	( ( 4.849	+	3.358 )	/ 2 )
	=	-6.52	/	4.1035
	=	-158.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Salarius Pharmaceuticals (FRA:FP1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Salarius Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Salarius Pharmaceuticals (FRA:FP1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (FRA:FP1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SLRX:USA

Address

2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021

Website

https://www.salariuspharma.com

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Salarius Pharmaceuticals (FRA:FP1) Headlines

No Headlines